MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - November 28, 2012) -
MorphoSys AG / MorphoSys to Present at an Upcoming Investor Conference.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX)
present at an upcoming international investor conference:
HSBC Healthcare Day
Date: November 29, 2012
Venue: Frankfurt, Germany
Participant: Dr. Claudia Gutjahr-Loser, Head of Corporate Communications &
The PDF version of the presentation will be provided at www.morphosys.com.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,
arYla®, Ylanthia®; and 100 billion high potentials® are registered
trademarks of MorphoSys AG Slonomics® is a registered trademark of
Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
Media Release (PDF): http://hugin.info/130295/R/1661063/538037.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE